These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 19541862)

  • 1. Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.
    Higgins MJ; Stearns V
    Clin Chem; 2009 Aug; 55(8):1453-5. PubMed ID: 19541862
    [No Abstract]   [Full Text] [Related]  

  • 2. Modification of tamoxifen response: what have we learned?
    Lash TL; Ahern TP; Cronin-Fenton D; Garne JP; Hamilton-Dutoit S; Kvistgaard ME; Rosenberg CL; Silliman RA; Sørensen HT
    J Clin Oncol; 2008 Apr; 26(10):1764-5; author reply 1765-6. PubMed ID: 18375910
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on CYP2D6 and its impact on tamoxifen therapy.
    Goetz MP
    Clin Adv Hematol Oncol; 2010 Aug; 8(8):536-8. PubMed ID: 20966889
    [No Abstract]   [Full Text] [Related]  

  • 5. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?
    Zembutsu H; Sasa M; Kiyotani K; Mushiroda T; Nakamura Y
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):185-93. PubMed ID: 21342038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen.
    Wang S; Somisetty VS; Bai B; Chernukhin I; Niskanen H; Kaikkonen MU; Bellet M; Carroll JS; Hurtado A
    Oncogene; 2020 Oct; 39(40):6300-6312. PubMed ID: 32843722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
    Hayes DF; Stearns V; Rae J; Flockhart D;
    J Natl Cancer Inst; 2008 May; 100(9):610-3. PubMed ID: 18445818
    [No Abstract]   [Full Text] [Related]  

  • 8. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies.
    Johnson JA; Hamadeh IS; Langaee TY
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638249
    [No Abstract]   [Full Text] [Related]  

  • 9. PharmGKB summary: tamoxifen pathway, pharmacokinetics.
    Klein DJ; Thorn CF; Desta Z; Flockhart DA; Altman RB; Klein TE
    Pharmacogenet Genomics; 2013 Nov; 23(11):643-7. PubMed ID: 23962908
    [No Abstract]   [Full Text] [Related]  

  • 10. Tamoxifen benefits and CYP2D6 testing in women with hormone receptor-positive breast cancer.
    Kaplan M; Mahon SM
    Clin J Oncol Nurs; 2013 Apr; 17(2):174-9. PubMed ID: 23538253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
    Singh MS; Francis PA; Michael M
    Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy.
    Thota K; Prasad K; Basaveswara Rao MV
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):343-350. PubMed ID: 29479969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2D6 and tamoxifen: DNA matters in breast cancer.
    Hoskins JM; Carey LA; McLeod HL
    Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients.
    Rae JM; Sikora MJ; Henry NL; Li L; Kim S; Oesterreich S; Skaar TC; Nguyen AT; Desta Z; Storniolo AM; Flockhart DA; Hayes DF; Stearns V;
    Pharmacogenomics J; 2009 Aug; 9(4):258-64. PubMed ID: 19421167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.
    Jordan VC
    Steroids; 2007 Nov; 72(13):829-42. PubMed ID: 17765940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized tamoxifen: a step closer but miles to go.
    Bardia A; Stearns V
    Clin Cancer Res; 2010 Sep; 16(17):4308-10. PubMed ID: 20651057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2D6 pharmacogenomics of tamoxifen treatment.
    Technol Eval Cent Assess Program Exec Summ; 2008 May; 23(1):1-4. PubMed ID: 18663817
    [No Abstract]   [Full Text] [Related]  

  • 19.
    Wei X; Cai J; Zhuang J; Zheng B; Sui Y; Zhang G; Lin Y; Sun H
    Pharmacogenomics; 2020 Jan; 21(1):43-53. PubMed ID: 31769341
    [No Abstract]   [Full Text] [Related]  

  • 20. CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients.
    Yazdi MF; Rafieian S; Gholi-Nataj M; Sheikhha MH; Nazari T; Neamatzadeh H
    Asian Pac J Cancer Prev; 2015; 16(15):6783-7. PubMed ID: 26434912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.